Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
51.94 (1y: +105%)
Market Cap 77.84 B P/E(ttm) 29.20
Enterprise Value 84.11 B P/B 8.50
GILD- NAS (USA)
Gilead Sciences Inc
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$51.94
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.22
GILD's Cash to Debt is ranked higher than
55% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. GILD: 0.22 )
GILD' s 10-Year Cash to Debt Range
Min: 0.22   Max: 3021.78
Current: 0.22
0.22
3021.78
Equity to Asset 0.438
GILD's Equity to Asset is ranked higher than
64% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.53 vs. GILD: 0.438 )
GILD' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.87
Current: 0.44
0.39
0.87
Interest Coverage 11.1
GILD's Interest Coverage is ranked higher than
73% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 11.1 )
GILD' s 10-Year Interest Coverage Range
Min: 11   Max: No Debt
Current: 11.1
F-Score: 7
Z-Score: 5.31
M-Score: -2.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 41.30
GILD's Operating margin (%) is ranked higher than
98% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. GILD: 41.30 )
GILD' s 10-Year Operating margin (%) Range
Min: -51.6   Max: 54.8
Current: 41.3
-51.6
54.8
Net-margin (%) 26.7
GILD's Net-margin (%) is ranked higher than
96% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. GILD: 26.7 )
GILD' s 10-Year Net-margin (%) Range
Min: -39.3   Max: 40.1
Current: 26.7
-39.3
40.1
ROE (%) 27.8
GILD's ROE (%) is ranked higher than
98% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 27.8 )
GILD' s 10-Year ROE (%) Range
Min: -65.5   Max: 49.5
Current: 27.8
-65.5
49.5
ROA (%) 12.2
GILD's ROA (%) is ranked higher than
95% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. GILD: 12.2 )
GILD' s 10-Year ROA (%) Range
Min: -29.1   Max: 28.7
Current: 12.2
-29.1
28.7
ROC (Joel Greenblatt) (%) 174.80
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 174.80 )
GILD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -110.6   Max: 180.4
Current: 174.8
-110.6
180.4
Revenue Growth (%) 13.1
GILD's Revenue Growth (%) is ranked higher than
92% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 13.1 )
GILD' s 10-Year Revenue Growth (%) Range
Min: 13.1   Max: 50.1
Current: 13.1
13.1
50.1
EBITDA Growth (%) 7.9
GILD's EBITDA Growth (%) is ranked higher than
92% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 7.9 )
GILD' s 10-Year EBITDA Growth (%) Range
Min: 7.9   Max: 77.8
Current: 7.9
7.9
77.8
EPS Growth (%) 3.8
GILD's EPS Growth (%) is ranked higher than
91% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 3.8 )
GILD' s 10-Year EPS Growth (%) Range
Min: 3.6   Max: 94.8
Current: 3.8
3.6
94.8
» GILD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

GILD Guru Trades in Q2 2012

John Rogers 6,164 sh (New)
Steven Cohen 1,977,292 sh (+1285.05%)
Jim Simons 2,580,824 sh (+61.08%)
John Griffin 4,115,000 sh (+38.55%)
David Rolfe 1,275,012 sh (+6.56%)
Pioneer Investments 324,700 sh (+1.07%)
John Hussman 650,000 sh (unchged)
Vanguard Health Care Fund 7,242,100 sh (unchged)
Jean-Marie Eveillard 200 sh (unchged)
Dodge & Cox Sold Out
John Burbank Sold Out
Ronald Muhlenkamp 252,110 sh (-0.15%)
RS Investment Management 144,800 sh (-0.88%)
Jeremy Grantham 553,358 sh (-17.08%)
Joel Greenblatt 81,707 sh (-45.82%)
Paul Tudor Jones 5,900 sh (-71.08%)
Louis Moore Bacon 150,000 sh (-76.92%)
» More
Q3 2012

GILD Guru Trades in Q3 2012

George Soros 25,000 sh (New)
Pioneer Investments 668,433 sh (+105.86%)
Steven Cohen 3,138,356 sh (+58.72%)
Jeremy Grantham 676,758 sh (+22.3%)
Jean-Marie Eveillard 200 sh (unchged)
Jim Simons Sold Out
Ronald Muhlenkamp Sold Out
Paul Tudor Jones Sold Out
John Rogers 6,028 sh (-2.21%)
Joel Greenblatt 73,416 sh (-10.15%)
RS Investment Management 127,700 sh (-11.81%)
John Griffin 3,560,000 sh (-13.49%)
Vanguard Health Care Fund 5,142,100 sh (-29%)
David Rolfe 899,059 sh (-29.49%)
John Hussman 350,000 sh (-46.15%)
Louis Moore Bacon 75,000 sh (-50%)
» More
Q4 2012

GILD Guru Trades in Q4 2012

John Burbank 104,900 sh (New)
Paul Tudor Jones 4,300 sh (New)
Mario Gabelli 6,185 sh (New)
Jim Simons 1,522,824 sh (New)
David Rolfe 1,161,109 sh (+29.15%)
RS Investment Management 164,900 sh (+29.13%)
John Griffin 4,000,000 sh (+12.36%)
George Soros 27,300 sh (+9.2%)
Jean-Marie Eveillard 200 sh (unchged)
John Rogers 6,028 sh (unchged)
Jeremy Grantham 912,138 sh (unchged)
Vanguard Health Care Fund 3,482,100 sh (unchged)
John Hussman 350,000 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments 569,106 sh (-14.86%)
Vanguard Health Care Fund 3,482,100 sh (-32.28%)
Joel Greenblatt 16,784 sh (-77.14%)
Steven Cohen 315,407 sh (-89.95%)
» More
Q1 2013

GILD Guru Trades in Q1 2013

Louis Moore Bacon 300,000 sh (New)
Mario Gabelli 27,200 sh (+119.89%)
Jeremy Grantham 2,353,984 sh (+29.04%)
Pioneer Investments 1,155,445 sh (+1.51%)
John Griffin 8,000,000 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
John Rogers 12,056 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
George Soros Sold Out
John Burbank Sold Out
David Rolfe 2,251,933 sh (-3.03%)
Vanguard Health Care Fund 6,721,600 sh (-3.48%)
John Hussman 558,000 sh (-20.29%)
RS Investment Management 227,840 sh (-30.92%)
Steven Cohen 244,861 sh (-61.18%)
Joel Greenblatt 9,784 sh (-70.85%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-03-31 Sold Out 0.3%$36.725 - $48.94 $ 51.9424%0
John Hussman 2013-03-31 Reduce -20.29%0.14%$36.725 - $48.94 $ 51.9424%558000
Joel Greenblatt 2013-03-31 Reduce -70.85%0.05%$36.725 - $48.94 $ 51.9424%9784
George Soros 2013-03-31 Sold Out 0.02%$36.725 - $48.94 $ 51.9424%0
Mario Gabelli 2013-03-31 Add 119.89%$36.725 - $48.94 $ 51.9424%27200
Vanguard Health Care Fund 2012-12-31 Reduce -32.28%0.48%$32.43 - $38.17 $ 51.9446%3482100
John Griffin 2012-12-31 Add 12.36%0.45%$32.43 - $38.17 $ 51.9446%4000000
John Burbank 2012-12-31 New Buy0.3%$32.43 - $38.17 $ 51.9446%104900
Joel Greenblatt 2012-12-31 Reduce -77.14%0.25%$32.43 - $38.17 $ 51.9446%16784
Mario Gabelli 2012-12-31 New Buy$32.43 - $38.17 $ 51.9446%6185
Ronald Muhlenkamp 2012-09-30 Sold Out 3%$25.34 - $33.89 $ 51.9482%0
Vanguard Health Care Fund 2012-09-30 Reduce -29%0.49%$25.34 - $33.89 $ 51.9482%5142100
John Hussman 2012-09-30 Reduce -46.15%0.29%$25.34 - $33.89 $ 51.9482%350000
George Soros 2012-09-30 New Buy0.03%$25.34 - $33.89 $ 51.9482%25000
John Griffin 2012-06-30 Add 38.55%0.89%$22.79 - $26.88 $ 51.94108%4115000
Joel Greenblatt 2012-06-30 Reduce -45.82%0.29%$22.79 - $26.88 $ 51.94108%81707
John Burbank 2012-06-30 Sold Out 0.21%$22.79 - $26.88 $ 51.94108%0
Dodge & Cox 2012-06-30 Sold Out 0.0012%$22.79 - $26.88 $ 51.94108%0
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Guru Investment Theses on Gilead Sciences Inc

Wedgewood Partners' David Rolfe Comments on Gilead Sciences - Nov 12, 2012

Gilead Sciences (GILD) was among our top performers during the third quarter. We believe that the stock's strong performance over the past three months, as well as the past year is quite warranted, as the company is on the cutting edge in developing a cure for the hepatitis C virus (HCV). The Company’s journey down this path began last November with their $11 billion purchase of Pharmasset, Inc. Pharmasset’s flagship drug candidate (PSI-7977, now GS-7977) is undergoing trials indicated for all-oral treatment of HCV and if ultimately approved by the FDA, Gilead could possess a multi-year, multi-billion dollar revenue opportunity. We believe that the market, more recently, has better recognized this opportunity, so we trimmed our positions during the quarter.

From Wedgewood Partners Third Quarter 2012 Review and Outlook.


Check out David Rolfe latest stock trades

Top Ranked Articles about Gilead Sciences Inc

Wedgewood Partners Trims High Gainers
May 31, 2013
Wedgewood Partners - Wedgewood Partners Trims High Gainers
As the CFA and CIO of Wedgewood Partners Inc., Guru David Rolfe has been managing Wedgewood's portfolio for over 18 years. Rolfe recently increased his position with 18 companies in the first quarter of 2013, but he didn’t buy any new stocks and traded very little otherwise. He did reduce his position with two high-gainers, Gilead Sciences Inc. (GILD), up 126% over the last 12 months and Charles Schwab Corp. (SCHW), up 67% over 12 months. Rolfe’s recently updated portfolio lists 22 stocks, with a total value of $2.98 billion and a quarter-over-quarter turnover of 22%. According to GuruFocus research, Guru David Rolfe made the following trades in the first quarter of 2013. Read more...
WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE
March 31, 2013
According to GuruFocus Insider Data, the largest CFO sells during the past week were: Read more...
Weekly Top Insider Sells： AAPL, GILD, BMRN, and PCLN
November 19, 2012
According to GuruFocus Insider Data, these are the largest insider sells during the past week. The overall trend of insiders is illustrated in the chart below: Read more...
Wedgewood Partners' David Rolfe Comments on Gilead Sciences
November 12, 2012
Gilead Sciences (GILD) was among our top performers during the third quarter. We believe that the stock's strong performance over the past three months, as well as the past year is quite warranted, as the company is on the cutting edge in developing a cure for the hepatitis C virus (HCV). The Company’s journey down this path began last November with their $11 billion purchase of Pharmasset, Inc. Pharmasset’s flagship drug candidate (PSI-7977, now GS-7977) is undergoing trials indicated for all-oral treatment of HCV and if ultimately approved by the FDA, Gilead could possess a multi-year, multi-billion dollar revenue opportunity. We believe that the market, more recently, has better recognized this opportunity, so we trimmed our positions during the quarter. Read more...
Edward Owens’ Vanguard Health Care Fund Does More Shedding Than Adding in Third Quarter
November 1, 2012
Edward Owens - Edward Owens’ Vanguard Health Care Fund Does More Shedding Than Adding In Third Quarter
Pennsylvania-based Vanguard Health Care Fund has reduced its stake of five companies out of the seven total transactions it reported recently for its third quarter portfolio update. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 29.20
GILD's P/E(ttm) is ranked higher than
66% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 26.90 vs. GILD: 29.20 )
GILD' s 10-Year P/E(ttm) Range
Min: 9.71   Max: 128.32
Current: 29.2
9.71
128.32
P/B 8.50
GILD's P/B is ranked higher than
53% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 3.56 vs. GILD: 8.50 )
GILD' s 10-Year P/B Range
Min: 4.15   Max: 50.25
Current: 8.5
4.15
50.25
P/S 8.40
GILD's P/S is ranked higher than
66% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. GILD: 8.40 )
GILD' s 10-Year P/S Range
Min: 3.48   Max: 32.24
Current: 8.4
3.48
32.24
PFCF 27.70
GILD's PFCF is ranked higher than
68% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. GILD: 27.70 )
GILD' s 10-Year PFCF Range
Min: 8.33   Max: 493.4
Current: 27.7
8.33
493.4
EV-to-EBIT 19.6
GILD's EV-to-EBIT is ranked higher than
70% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 22.58 vs. GILD: 19.6 )
GILD' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 471.7
Current: 19.6
6.8
471.7
PEG 1.8
GILD's PEG is ranked higher than
69% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 1.80 vs. GILD: 1.8 )
GILD' s 10-Year PEG Range
Min: 0.3   Max: 1.81
Current: 1.8
0.3
1.81
Shiller P/E 34.8
GILD's Shiller P/E is ranked lower than
100% of the Companies
in the Global Biotechnology industry.

( Industry Median: vs. GILD: 34.8 )
GILD' s 10-Year Shiller P/E Range
Min: 17.87   Max: 1840.8
Current: 34.8
17.87
1840.8

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 36.3
GILD's Price/Net Current Asset Value is ranked higher than
71% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: 45.80 vs. GILD: 36.3 )
GILD' s 10-Year Price/Net Current Asset Value Range
Min: 14.9   Max: 86.4
Current: 36.3
14.9
86.4
Price/DCF (Projected) 1.8
GILD's Price/DCF (Projected) is ranked higher than
79% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. GILD: 1.8 )
GILD' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 16.2
Current: 1.8
0.8
16.2
Price/Median PS Value 0.7
GILD's Price/Median PS Value is ranked higher than
83% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. GILD: 0.7 )
GILD' s 10-Year Price/Median PS Value Range
Min: 0.3   Max: 2.6
Current: 0.7
0.3
2.6
Price/Peter Lynch Fair Value 1.7
GILD's Price/Peter Lynch Fair Value is ranked higher than
63% of the 59 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. GILD: 1.7 )
GILD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4   Max: 1.3
Current: 1.7
0.4
1.3
Earnings Yield (Greenblatt) 5.10
GILD's Earnings Yield (Greenblatt) is ranked higher than
86% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 5.10 )
GILD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 14.8
Current: 5.1
0.2
14.8
Forward Rate of Return (Yacktman) 19.95
GILD's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 19.95 )
GILD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.4   Max: 54
Current: 19.95
-0.4
54

Business Description

Gilead Sciences, Inc. was incorporated in Delaware on June 22, 1987. It is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors; ea
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, BIIB, CELG, CMXHY
Traded in other countries:GIS.Germany
» More Articles for GILD

Headlines

Articles On GuruFocus.com
Wedgewood Partners Trims High Gainers May 31 2013 
comment on GILD May 22 2013 
Weekly CEO Sells Highlight: Activision Blizzard, Nielsen Holdings NV, Gilead Sciences, Autodesk Apr 08 2013 
WEEKLY CFO SELLS HIGHLIGHT: ANIK, GILD, PETM, NKE, ADBE Mar 31 2013 
comment on GILD Mar 24 2013 
Stevie Cohen On Board with Real Estate Betting, Despite SEC Probe Jan 18 2013 
Weekly Top Insider Sells: NOW, FB, GILD, and ISRG Nov 26 2012 
Weekly Top Insider Sells： AAPL, GILD, BMRN, and PCLN Nov 19 2012 
Wedgewood Partners' David Rolfe Comments on Gilead Sciences Nov 12 2012 
Wedgewood Partners Third Quarter 2012 Review and Outlook Nov 12 2012 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK